Globus Medical (GMED) Q2 2025: Nevro Adds $95M, Accelerating Musculoskeletal Platform Integration

August 7, 2025 | By EarningsIQ Research

Globus Medical’s Q2 marked a pivotal integration milestone as Nevro contributed $95 million in its first full quarter, propelling above-market U.S. spine growth and solidifying the company’s musculoskeletal platform ambitions. With operational hurdles receding and new leadership at the helm, GMED sharpened its focus on organic innovation, manufacturing leverage, and commercial execution. The company’s reaffirmed guidance and robust cash flow signal confidence in its multi-segment growth strategy, even as international and enabling tech segments face nuanced headwinds and opportunities.

Summary

• Platform Expansion Accelerates: Nevro’s integration broadens GMED’s continuum of musculoskeletal care and energizes commercial momentum.
• Manufacturing and Supply Chain Stabilize: U.S. spine and trauma outpace the market as inventory and set availability normalize.
• Leadership Transition Sharpens Focus: New CEO Keith Pfeil signals continuity in strategy with increased investor engagement and operational discipline.

Performance Analysis

Globus Medical delivered a multi-dimensional quarter, with total sales reaching $745 million and non-GAAP EPS up 14.1% year over year, driven by the first full-quarter inclusion of Nevro and robust U.S. spine and trauma growth. The base business (excluding Nevro) posted 3.3% reported revenue growth, or 4.9% day-adjusted, reflecting resilience in the core spine franchise despite one fewer selling day in the U.S. and two fewer in Japan. Nevro, neuromodulation business, contributed $95 million, offering immediate scale and strategic synergy in pain management.

Operationally, U.S. spine led with 5.7% reported and 7.4% day-adjusted growth, underpinned by new product launches (notably the DuraPro Drill System), competitive rep recruitment, and improved supply chain execution. Enabling Technologies, robotics and imaging business, rebounded 58% sequentially but remained down 4% YoY, reflecting elongated selling cycles and deal timing rather than competitive losses. International revenue grew 11% as reported, though constant currency growth was muted at 7.5%, with EMEA strength offset by LATAM softness and ongoing distributor-to-direct transitions.

• U.S. Spine Momentum Sustains: 19 consecutive weeks of implant growth and strong July/August trends position the segment for continued market share gains.
• Trauma and Innovation Drive Density: Trauma revenue up 35% YoY, aided by differentiated products and a targeted density model for account penetration.
• Enabling Tech Pipeline Remains Robust: Sequential recovery and positive customer feedback set up a potential return to double-digit growth in the back half.

Adjusted EBITDA margin for the base business expanded 210 basis points to 32.3%, while Nevro finished at near break-even EBITDA, reflecting early synergy capture and disciplined cost actions. Free cash flow remained strong at $31 million, supporting ongoing investment and share repurchases.

Executive Commentary

Strategic Positioning

1. Nevro Integration and Platform Expansion

The Nevro acquisition, spinal cord stimulation and neuromodulation business, marks a deliberate expansion of GMED’s musculoskeletal care continuum. Leadership underscored the strategic rationale: Nevro’s differentiated technology and high-frequency therapy address patient populations not served by surgery, while the integration unlocks commercial and R&D synergies. Early feedback from pain physicians and surgeons has been “universally positive,” and leadership is recasting Nevro’s product development with a focus on organic innovation and cost discipline. The transaction also delivered $141 million in deferred tax assets, providing long-term cash tax savings.

2. U.S. Spine and Trauma Outperformance

GMED’s core U.S. spine and trauma segments are driving above-market growth, supported by new product launches, targeted rep hiring, and improved inventory management. The DuraPro Drill System, oscillating drill technology, is gaining rapid traction via surgeon testimonials, while trauma’s density model and differentiated implants (Audubon nails, Anthem plates) are opening new accounts and attracting top sales talent. Leadership highlighted 19 consecutive weeks of implant growth, reflecting both operational stability and commercial execution.

3. Manufacturing and Cost Structure Leverage

Ongoing manufacturing insourcing and integration initiatives are central to GMED’s margin expansion thesis, with the company targeting a return to mid-70s adjusted gross profit over the next 12-18 months. Machines are coming online in Pennsylvania and Ohio, and as teams gain efficiency, incremental output and cost savings are expected to flow through the P&L in 2026. Synergy capture from the NuVasive and Nevro deals is already evident in lower R&D and SG&A as a percentage of sales.

4. Enabling Technologies and Robotics

Enabling Technologies (robotics, imaging, navigation) rebounded sequentially but remain challenged by elongated sales cycles, not competitive losses. Leadership remains bullish on the pipeline, citing positive customer feedback and the launch of the Excelsis XR augmented reality headset, which integrates with the Excelsis ecosystem for real-time surgical visualization. The company expects robotic surgery to become the standard of care in spine, with nearly 110,000 procedures performed to date.

5. International Focus and Integration

GMED is prioritizing depth over breadth internationally, focusing on key EMEA and APAC markets while consolidating distributors and transitioning to direct sales. While this approach may create near-term growth noise, leadership believes it’s critical for sustainable market share gains and operational control. Integration of international sales forces and systems remains a work in progress, with supply chain normalization expected to drive incremental growth in H2.

Key Considerations

GMED’s Q2 reflects a company at an inflection point, balancing the integration of transformative acquisitions with operational execution and innovation across core and emerging segments.

Key Considerations:

• Synergy Realization Pace: Early cost actions at Nevro drove near break-even EBITDA, but leadership remains cautious about potential sales impact as integration deepens.
• Spine Franchise Durability: Consistent implant growth and strong July/August momentum suggest sustained share gains, but competitive rep recruitment and surgeon engagement will be critical to maintain trajectory.
• Enabling Tech Execution: The ability to convert pipeline opportunities and accelerate deal closures will determine whether robotics and imaging return to double-digit growth in H2.
• International Integration Risks: Transitioning from distributor to direct models and focusing on major markets may dampen near-term growth but is positioned for long-term share capture.
• Capital Allocation Discipline: Continued investment in R&D, manufacturing, and share repurchases, all while remaining debt-free, underscores a commitment to long-term profitability and flexibility.

Risks

Integration complexity remains a central risk, particularly as Nevro and NuVasive cost actions could unintentionally disrupt sales momentum or talent retention. Elongated capital cycles in enabling technologies and international market volatility (notably in LATAM and currency headwinds) add uncertainty. Leadership’s cautious optimism is warranted, as synergy capture and organic growth must be balanced against execution risk and evolving competitive dynamics.

Forward Outlook

For Q3 2025, GMED guided to:

• Continued above-market growth in U.S. spine and trauma
• Sequential improvement in international as supply and integration progress

For full-year 2025, management reaffirmed guidance:

• Net sales of $2.8 to $2.9 billion
• Non-GAAP EPS of $3.00 to $3.30

Management highlighted several factors that shape the outlook:

• Synergy actions at Nevro and NuVasive expected to drive incremental profit in H2 and 2026
• Enabling tech pipeline and product launches underpin confidence in H2 acceleration

Takeaways

GMED’s Q2 demonstrates the early fruits of platform expansion, with Nevro integration, core spine momentum, and operational discipline positioning the company for multi-segment growth.

• Platform Synergy Realization: Nevro’s $95 million contribution and early cost actions validate the strategic rationale, but sustained integration will be critical for long-term accretion.
• Organic Growth Engines: Spine and trauma outperformance, new product launches, and a resilient sales force drive confidence in the core franchise.
• Execution Watchpoints: Investors should monitor the pace of enabling tech deal closures, international direct transitions, and further synergy realization as key levers for future upside or risk.

Conclusion

Globus Medical’s Q2 marks a turning point as the company operationalizes its multi-year M&A strategy, returning to above-market growth in core segments while leveraging integration and innovation to drive future value. Leadership’s focus on execution, synergy capture, and disciplined capital allocation will be decisive in realizing the full potential of its expanded platform.

Industry Read-Through

GMED’s results reinforce the premium placed on platform breadth and vertical integration across medtech, as companies seek to address the full continuum of care and leverage scale for margin expansion. The successful absorption of Nevro and NuVasive, along with the stabilization of supply chains, highlights the growing importance of operational agility and disciplined integration in the sector. Robotics and enabling technologies remain a battleground, with deal timing and capital cycles dictating near-term volatility. For peers, the emphasis on depth in key international markets and a density-driven commercial model offers a blueprint for sustainable share capture in a consolidating landscape.

GMED Health Care Medical Devices Musculoskeletal Robotics Neuromodulation Integration Platform